Browse RGS4

Summary
SymbolRGS4
Nameregulator of G-protein signaling 4
Aliases regulator of G-protein signalling 4; schizophrenia disorder 9
Chromosomal Location1q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF00615 Regulator of G protein signaling domain
Function

Inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits thereby driving them into their inactive GDP-bound form. Activity on G(z)-alpha is inhibited by phosphorylation of the G-protein. Activity on G(z)-alpha and G(i)-alpha-1 is inhibited by palmitoylation of the G-protein.

> Gene Ontology
 
Biological Process GO:0000188 inactivation of MAPK activity
GO:0001933 negative regulation of protein phosphorylation
GO:0006469 negative regulation of protein kinase activity
GO:0008277 regulation of G-protein coupled receptor protein signaling pathway
GO:0033673 negative regulation of kinase activity
GO:0042326 negative regulation of phosphorylation
GO:0043405 regulation of MAP kinase activity
GO:0043407 negative regulation of MAP kinase activity
GO:0043409 negative regulation of MAPK cascade
GO:0045744 negative regulation of G-protein coupled receptor protein signaling pathway
GO:0051348 negative regulation of transferase activity
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071901 negative regulation of protein serine/threonine kinase activity
GO:1902532 negative regulation of intracellular signal transduction
Molecular Function GO:0001965 G-protein alpha-subunit binding
GO:0005096 GTPase activator activity
GO:0005516 calmodulin binding
GO:0008047 enzyme activator activity
GO:0030695 GTPase regulator activity
GO:0060589 nucleoside-triphosphatase regulator activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-418594: G alpha (i) signalling events
R-HSA-418597: G alpha (z) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolRGS4
Nameregulator of G-protein signaling 4
Aliases regulator of G-protein signalling 4; schizophrenia disorder 9
Chromosomal Location1q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RGS4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolRGS4
Nameregulator of G-protein signaling 4
Aliases regulator of G-protein signalling 4; schizophrenia disorder 9
Chromosomal Location1q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RGS4 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolRGS4
Nameregulator of G-protein signaling 4
Aliases regulator of G-protein signalling 4; schizophrenia disorder 9
Chromosomal Location1q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RGS4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.5540.194
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.8810.285
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3080.629
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.1160.0116
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.7990.0966
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2580.835
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1580.797
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-1.0610.296
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.4220.216
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.2750.803
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9230.502
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0550.812
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RGS4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolRGS4
Nameregulator of G-protein signaling 4
Aliases regulator of G-protein signalling 4; schizophrenia disorder 9
Chromosomal Location1q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RGS4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRGS4
Nameregulator of G-protein signaling 4
Aliases regulator of G-protein signalling 4; schizophrenia disorder 9
Chromosomal Location1q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RGS4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RGS4.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRGS4
Nameregulator of G-protein signaling 4
Aliases regulator of G-protein signalling 4; schizophrenia disorder 9
Chromosomal Location1q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RGS4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRGS4
Nameregulator of G-protein signaling 4
Aliases regulator of G-protein signalling 4; schizophrenia disorder 9
Chromosomal Location1q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RGS4 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRGS4
Nameregulator of G-protein signaling 4
Aliases regulator of G-protein signalling 4; schizophrenia disorder 9
Chromosomal Location1q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RGS4 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRGS4
Nameregulator of G-protein signaling 4
Aliases regulator of G-protein signalling 4; schizophrenia disorder 9
Chromosomal Location1q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RGS4 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.